Life Groenkloof Hospital

Recent papers from Life Groenkloof Hospital

1. Reframing Trisomy 13 and 18 Care: Moving Beyond the Myth of “Incompatibility With Life” in a South African and Low‐and Middle‐Income Country ContextAmerican Journal of Medical Genetics Part A · 2026
2. Classifying seizures in practice: Testing the 2025 ILAE framework among clinicians in South AfricaEpilepsia · 2026
3. Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II StudyJCO Oncology Practice · 2026
4. Can AI Express Empathy? Computational Insights from Mental Health DialoguesJournal of Technology in Behavioral Science · 2026
5. Negative pressure wound therapy use: recommendations from a South African panel of expertsJournal of Wound Care · 2026
6. Using the Mantlwane game as a culturally responsive pedagogical tool for teaching Sepedi in Foundation Phase classroomsSouth African Journal of African Languages · 2026
7. Visible Light Protection Strategies for Diverse PopulationsDermatology and Therapy · 2026
8. Negative Pressure Wound Therapy With Instillation and Closed Incision Negative Pressure Therapy Use in South Africa: Expert Panel RecommendationsInternational Wound Journal · 2025
9. Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis TreatmentClinical Infectious Diseases · 2025
10. Uptake and 24-month outcomes of dolutegravir- versus lopinavir-based second-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study and emulated target trialOpen Forum Infectious Diseases · 2025
11. Non-autoimmune, insulin-deficient diabetes in children and young adults in Africa: evidence from the Young-Onset Diabetes in sub-Saharan Africa (YODA) cross-sectional studyThe Lancet Diabetes & Endocrinology · 2025
12. The elastic properties of the tendinous and capsular layers of the rotator cuff complex using fresh tissue—a biomechanical studyEuropean Journal of Orthopaedic Surgery & Traumatology · 2025
13. Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort AnalysisClinical Infectious Diseases · 2025
14. Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 studyPLoS ONE · 2024
15. Understanding the impact of pandemics on long-term medication adherence: directly observed therapy in a tuberculosis treatment cohort pre- and post-COVID-19 lockdownsBMC Infectious Diseases · 2024
16. Patient and provider perceptions of the relationship between alcohol use and TB and readiness for treatment: a qualitative study in South AfricaBMC Public Health · 2024
17. Emerging patterns of inflammatory bowel disease in sub-Saharan Africa: 175 cases from an IBD networkJournal of Crohn s and Colitis · 2024
18. Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.Journal of Clinical Oncology · 2024
19. The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic reviewBMC Women s Health · 2024
20. Bad company? The pericardium microbiome in people investigated for tuberculosis pericarditis in an HIV-prevalent setting2024